ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Dexpramipexole could be a promising treatment for eosinophilic asthma
May 20, 2021Oral doses of dexpramipexole lowered eosinophil counts by up to 80 percent and showed signs of improving lung function in a Phase II eosinophilic asthma trial. -
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome
April 25, 2019PITTSBURGH--(BUSINESS WIRE)-- Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for ...
Pharma Sources Insight January 2025
